Moreover, second-line therapies are personalized according to clinical and biochemical individual paraments as well as tumor molecular and morphology features (43, 44) to optimize the acromegaly outcome and to reduce the time of exposure to GH and IGF-I hypersecretion. This evidence concerns the gene GH1 and neoplasm.